AKERO THERAPEUTICS INC (AKRO) Forecast, Price Target & Analyst Ratings
NASDAQ:AKRO • US00973Y1082
54.65 USD
+0.1 (+0.18%)
At close: Dec 8, 2025
54.7 USD
+0.05 (+0.09%)
After Hours: 12/8/2025, 8:00:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AKERO THERAPEUTICS INC (AKRO).
Forecast Snapshot
Consensus Price Target
$64.26
+ 17.58% Upside
Next Earnings Forecast
Release DateFeb 26, 2026
PeriodQ4 / 2025
EPS Estimate-$0.96
Revenue Estimate
ChartMill Buy Consensus
72.50%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$64.26
Upside
+ 17.58%
From current price of $54.65 to mean target of $64.26, Based on 16 analyst forecasts
Low
$54.54
Median
$59.16
High
$114.45
Price Target Revisions
1 Month
0.00%
3 Months
-15.18%
Price Target Summary
16 Wall Street analysts provided a forecast for the next 12 months for AKRO. The average price target is 64.26 USD. This implies a price increase of 17.58% is expected in the next year compared to the current price of 54.65.
The average price target has been revised downward by 15.18% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
72.50%
AKRO was analyzed by 16 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about AKRO.
In the previous month the buy percentage consensus was at a similar level.
AKRO was analyzed by 16 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-10-10 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2025-10-10 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-10-09 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2025-10-09 | Jefferies | Downgrade | Buy -> Hold |
| 2025-08-04 | TD Cowen | Initiate | Buy |
| 2025-05-27 | B of A Securities | Maintains | Buy -> Buy |
| 2025-05-13 | Citigroup | Maintains | Buy -> Buy |
| 2025-03-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-31 | UBS | Maintains | Buy -> Buy |
| 2025-01-30 | B of A Securities | Upgrade | Neutral -> Buy |
| 2025-01-28 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-01-28 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-01-28 | Citigroup | Maintains | Buy -> Buy |
| 2025-01-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-18 | Citigroup | Initiate | Buy |
| 2024-11-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-20 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-06-12 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-06-11 | Wolfe Research | Initiate | Outperform |
| 2024-06-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | Evercore ISI Group | Maintains | Outperform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateFeb 26, 2026
PeriodQ4 / 2025
EPS Estimate-$0.96
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q3.15%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
4.20%
EPS (3 Months)
1.05%
Next Earnings Summary
AKRO is expected to report earnings on 2/26/2026. The consensus EPS estimate for the next earnings is -0.96 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 364.77% | N/A 138.25% | N/A 82.48% | N/A -13.38% | |||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | -80.13M -73.23% | -100.85M -25.86% | -115.12M -14.15% | -172.841M -50.14% | -285.405M -65.13% | N/A -24.11% | N/A -8.97% | N/A -5.26% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.56M | -13.78M -202.19% | -45.65M -231.28% | -80.15M -75.58% | -100.89M -25.88% | -115.16M -14.14% | -172.87M -50.11% | -285.423M -65.11% | N/A -21.08% | N/A -13.12% | N/A -9.87% | N/A 20.72% | N/A 121.87% | N/A 796.96% | N/A 127.08% | N/A -31.51% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.48 13.42% | -2.89 -16.53% | -2.92 -1.04% | -2.85 2.40% | -3.75 -31.58% | N/A -1.02% | N/A -16.05% | N/A -4.78% | N/A 39.25% | N/A 175.64% | N/A 335.42% | N/A 94.85% | N/A -51.66% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.96 3.15% | -1.00 -10.69% | -1.03 -19.40% | -1.05 -7.55% | -1.10 -14.89% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -94.804M -21.53% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -90.847M -16.43% | -93.005M -14.99% | -95.407M -17.97% | -97.996M -8.60% | -98.022M -7.90% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-7.10%
EPS Next 5 Year
20.73%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-10.65%
EBIT Next 5 Year
N/A
AKERO THERAPEUTICS INC / AKRO Forecast FAQ
What do analysts expect the price target to be for AKERO THERAPEUTICS INC (AKRO)?
16 analysts have analysed AKRO and the average price target is 64.26 USD. This implies a price increase of 17.58% is expected in the next year compared to the current price of 54.65.
Can you provide the upcoming earnings date for AKERO THERAPEUTICS INC?
AKERO THERAPEUTICS INC (AKRO) will report earnings on 2026-02-26, after the market close.
What are the consensus estimates for AKRO stock next earnings?
The consensus EPS estimate for the next earnings of AKERO THERAPEUTICS INC (AKRO) is -0.96 USD and the consensus revenue estimate is 0 USD.